New combo therapy for mesothelioma shows early promise

NCT ID NCT04897022

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether combining the immunotherapy drug pembrolizumab with a precise type of radiation (IMPRINT) is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. The study involves 7 participants whose cancer cannot be removed by surgery and who have already tried at least one other treatment. The main goal is to find the highest radiation dose that causes few or mild side effects when given with pembrolizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (an immunotherapy drug) and intensity-modulated pleural radiation therapy (targeted radiation)
What this could lead to: If successful, this could point toward a safer, more effective combination treatment for malignant pleural mesothelioma, a rare and aggressive cancer.
What could go wrong: This is a very early (Phase 1) trial with only 7 participants, so results may not apply broadly. The combination may cause serious side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLEURAL MESOTHELIOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited protocol activities)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.